A Phase 1/2, randomized, active-controlled, dose escalation, multicenter trial study of Z-1018 compared to Shingrix in healthy adults aged 50 to 69 years
Latest Information Update: 17 Jan 2025
At a glance
- Drugs Z 1018 (Primary)
- Indications Herpes zoster; Varicella zoster virus infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 13 Jan 2025 According to a Dynavax media release, In the fourth quarter of 2024, the Company completed enrollment in the trial, and Dynavax anticipates reporting top line immunogenicity and safety data in the third quarter of 2025.
- 13 Jan 2025 According to a Dynavax media release, Status changed from recruiting to active, no longer recruiting.
- 27 Jun 2024 Status changed from planning to recruiting, according to a Dynavax media release.